Raymond James & Associates Buys New Holdings in Evolus Inc (EOLS)

Share on StockTwits

Raymond James & Associates bought a new position in shares of Evolus Inc (NASDAQ:EOLS) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,681 shares of the company’s stock, valued at approximately $327,000.

Several other hedge funds also recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in Evolus by 58.7% in the 2nd quarter. BlackRock Inc. now owns 300,509 shares of the company’s stock valued at $8,411,000 after purchasing an additional 111,123 shares during the period. Northern Trust Corp bought a new stake in Evolus in the 1st quarter valued at about $516,000. California Public Employees Retirement System bought a new stake in Evolus in the 1st quarter valued at about $293,000. Spark Investment Management LLC bought a new stake in Evolus in the 2nd quarter valued at about $531,000. Finally, Bank of Montreal Can bought a new stake in Evolus in the 2nd quarter valued at about $512,000. 13.13% of the stock is owned by institutional investors and hedge funds.

In other news, insider Michael M. Jafar purchased 12,800 shares of the business’s stock in a transaction dated Friday, September 14th. The stock was bought at an average price of $20.83 per share, with a total value of $266,624.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kristine Romine purchased 10,000 shares of the business’s stock in a transaction dated Wednesday, August 22nd. The shares were purchased at an average cost of $19.83 per share, with a total value of $198,300.00. The disclosure for this purchase can be found here.

NASDAQ EOLS opened at $14.10 on Wednesday. Evolus Inc has a 12-month low of $6.75 and a 12-month high of $39.50.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Thursday, August 2nd. The company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.05). As a group, research analysts forecast that Evolus Inc will post -1.76 EPS for the current fiscal year.

A number of analysts have issued reports on EOLS shares. Cantor Fitzgerald reissued a “buy” rating and issued a $35.00 price objective on shares of Evolus in a report on Monday, September 17th. SunTrust Banks reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Monday, August 6th. Finally, Zacks Investment Research raised shares of Evolus from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Tuesday, July 17th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $30.40.

Evolus Company Profile

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Featured Story: How does inflation affect different investments?

Institutional Ownership by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply